
FDA Authorizes a Prescription Digital Therapeutic for Insomnia
On Thursday, March 26, the FDA granted authorization for SomrystTM, a prescription-only digital therapeutic for treatment of chronic insomnia in patients aged 22 years or older.
On Thursday, March 26, the FDA granted authorization for SomrystTM, a prescription-only digital therapeutic that can be accessed on a smart phone or tablet for treatment of chronic insomnia in patients aged 22 years or older. Clinical guidelines from the
The FDA authorization was based on two randomized controlled trials comprising more than 1400 adults with chronic insomnia. Findings from the first trial suggest that patients saw improvements in
Somryst should be used only under the supervised care of a clinician. Psychiatric Times Advisory Board member John Torous, MD, MBI, director of the digital psychiatry division, Department of Psychiatry, Beth Israel Deaconess Medical Center, a Harvard Medical School affiliated teaching hospital, warns that “The usage data collected in therapy lessons by Somryst are not intended to be used as a standalone assessment of treatment progress.”
Contraindication for use include:
• Any disorder exacerbated by sleep restriction (eg, bipolar disorder, schizophrenia, other psychotic spectrum disorders)
• Untreated obstructive sleep apnea
• Parasomnias
• Seizure disorders
• Individuals at high risk of falls
• Pregnant women
• Person with unstable of degenerative illness judged to be worsened by sleep restriction.
Torous noted, “The mental health field has a rich history of using technology as part of care for insomnia, so this news is of course welcome. But it remains to be seen whether this will actually increase access to quality of care. Real world data will be critical for psychiatrists about the implementation challenges and patient experiences with this new product.”
References:
1. Rittenband LM, Thorndike FP, Ingersoll KS, et al.
2. Christensen H, Batterham PJ, Gosling JA, et al.
Newsletter
Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.